Valentine Karen 4
4 · CONSTELLATION PHARMACEUTICALS INC · Filed May 7, 2020
Insider Transaction Report
Form 4
Valentine Karen
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2020-05-06$11.50/sh+10,099$116,139→ 10,099 total - Exercise/Conversion
Common Stock
2020-05-06$8.76/sh+2,467$21,611→ 12,566 total - Sale
Common Stock
2020-05-06$40.10/sh−12,566$503,897→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-05-05−4,744→ 109,241 totalExercise: $11.50Exp: 2028-07-18→ Common Stock (4,744 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2020-05-06−10,099→ 99,142 totalExercise: $11.50Exp: 2028-07-18→ Common Stock (10,099 underlying) - Exercise/Conversion
Common Stock
2020-05-05$11.50/sh+4,744$54,556→ 4,744 total - Sale
Common Stock
2020-05-05$40.01/sh−4,744$189,817→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2020-05-06−2,467→ 22,425 totalExercise: $8.76Exp: 2029-03-06→ Common Stock (2,467 underlying)
Footnotes (5)
- [F1]These trades were made pursuant to a Rule 10b5-1 trading plan.
- [F2]This transaction was executed in multiple trades at prices ranging from $40.00 to $40.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $40.00 to $40.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This option was granted on July 19, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through July 16, 2022.
- [F5]This option was granted on March 7, 2019. The shares underlying the option are scheduled to vest in equal quarterly installments through March 7, 2023.